WD 920
Alternative Names: WD-920Latest Information Update: 24 Feb 2026
At a glance
- Originator Ningbo Wenda Pharma
- Class Antiparkinsonians; Small molecules; Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Parkinson's disease; Stroke
Most Recent Events
- 24 Feb 2026 Preclinical trials in Amyotrophic lateral sclerosis in China (unspecified route) before February 2026 (Ningbo Wenda Pharma pipeline, February 2026)
- 24 Feb 2026 Preclinical trials in Parkinson's disease in China (unspecified route) before February 2026 (Ningbo Wenda Pharma pipeline, February 2026)
- 24 Feb 2026 Preclinical trials in Stroke in China (unspecified route) before February 2026 (Ningbo Wenda Pharma pipeline, February 2026)